Role of drug metabolism in drug discovery and development
暂无分享,去创建一个
[1] J. Vacca,et al. P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[2] P. Watkins,et al. THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.
[3] O. Olesen,et al. Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes , 1999, Pharmacology.
[4] K. Griffin,et al. Molecular mechanisms of cytochrome P-450 induction by xenobiotics: An expanded role for nuclear hormone receptors. , 1999, Molecular pharmacology.
[5] Shiew-Mei Huang,et al. FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on Labeling , 1999, Journal of clinical pharmacology.
[6] M. Ingelman-Sundberg,et al. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.
[7] A. Alex,et al. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[8] P N Judson,et al. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.
[9] A. Y. Lu,et al. Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.
[10] A. Hsu,et al. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. , 1998, Clinical pharmacokinetics.
[11] Y. Sugiyama,et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.
[12] M. Ackland,et al. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[13] W. Trager,et al. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. , 1998, Chemical research in toxicology.
[14] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[15] A. Y. Lu,et al. Role of pharmacokinetics and metabolism in drug discovery and development. , 1997, Pharmacological reviews.
[16] Barry C. Jones,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .
[17] F. Beland,et al. Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. , 1997, Carcinogenesis.
[18] A. D. Rodrigues,et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir , 1997, Antimicrobial agents and chemotherapy.
[19] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[20] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[21] M. Pirmohamed,et al. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. , 2003, British journal of clinical pharmacology.
[22] D. Walker,et al. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics , 1996, Medicinal research reviews.
[23] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[24] J. Caldwell. The Role of Drug Metabolism in Drug Discovery and Development , 1996 .
[25] P. Neuvonen,et al. Rifampin drastically reduces plasma concentrations and effects of oral midazolam , 1996, Clinical pharmacology and therapeutics.
[26] E. Gallagher,et al. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. , 1995, Pharmacogenetics.
[27] P. Chakravarty,et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[28] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[29] K. Korzekwa,et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.
[30] J. Miners,et al. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. , 1994, British journal of clinical pharmacology.
[31] W. Trager,et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[32] M. J. Coon,et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.
[33] F. Guengerich. Metabolic activation of carcinogens. , 1992, Pharmacology & therapeutics.
[34] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[35] F. Guengerich. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. , 1990, Chemical research in toxicology.
[36] C. Westerlund,et al. Quantitative relationships between structure and microsomal oxidation rate of 1,4-dihydropyridines. , 1986, Chemico-biological interactions.
[37] L. Pershing,et al. Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. , 1982, Xenobiotica; the fate of foreign compounds in biological systems.
[38] J. Mccall,et al. Sulfation of minoxidil by liver sulfotransferase. , 1982, Biochemical pharmacology.
[39] S. Sligar,et al. Substrate interaction with cytochrome P-450. , 1981, Pharmacology & therapeutics.